SUBSCRIBE
SUBSCRIBE

Dermatology

Loss of one drug name. Ban on a drug or its shortage. Exclusion from the list of free drugs available under the medical social program.
Rare diseases
InflaRx Axes Rare Skin Disease Study on Disappointing Late-Stage Data
InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.
May 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
Dr. Mariusz Sapijaszko elected President of the Canadian Dermatology Association
June 29, 2026
 · 
2 min read
Press Releases
Rapalogix Health Raises $20 Million in Series A Financing to Redefine the Future of Longevity-Based Skin Health
June 23, 2026
 · 
5 min read
Press Releases
Takeda’s Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
June 23, 2026
 · 
14 min read
Press Releases
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
June 12, 2026
 · 
7 min read
Press Releases
Crescita Therapeutics Inc. Announces Closing of Arrangement
June 4, 2026
 · 
3 min read
Press Releases
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
June 2, 2026
 · 
5 min read
Press Releases
Canadian Dermatology Association in Partnership with Melanoma Canada Offer Free Skin Cancer Screenings on Parliament Hill
May 27, 2026
 · 
4 min read
Press Releases
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
 · 
2 min read
Press Releases
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
May 24, 2026
 · 
6 min read
Press Releases
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
May 24, 2026
 · 
5 min read
Press Releases
BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data
May 19, 2026
 · 
21 min read
Press Releases
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
May 14, 2026
 · 
7 min read
Press Releases
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
May 14, 2026
 · 
18 min read
Press Releases
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
May 13, 2026
 · 
3 min read
Press Releases
Crescita Reports First Quarter 2026 Results
May 11, 2026
 · 
17 min read
Press Releases
TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis
May 8, 2026
 · 
3 min read
Press Releases
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
May 7, 2026
 · 
8 min read
Press Releases
Orvida Pharma to Present Functional Endpoint Development Data in Rare Palmoplantar Skin Disorders at the 83rd Annual Meeting of the Society for Investigative Dermatology and the 2026 Epidermal Differentiation Disorders Symposium
May 5, 2026
 · 
3 min read
Press Releases
LEO Pharma Delivers 9% Revenue Growth at CER in Q1 2026 and Strengthens Innovation Pipeline
May 5, 2026
 · 
3 min read
Press Releases
Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting
May 4, 2026
 · 
2 min read
Load More